Explore

Rapid Read Rapid Read
Pharvaris Plans FDA Filings for Hereditary Angioedema Drug Deucrictibant After Positive Phase 3 Trial Results

Pharvaris Plans FDA Filings for Hereditary Angioedema Drug Deucrictibant After Positive Phase 3 Trial Results

Swiss biotech Pharvaris has reported positive data from a Phase 3 trial of its extended-release formulation of deucrictibant, a bradykinin B2 receptor antagonist, for hereditary angioedema (HAE). The drug achieved an 83% reduction in monthly HAE attacks compared to placebo in the CHAPTER-3 study, which included all three types of HAE. This pivotal trial win sets the stage for marketing applications in the U.S. next year. Pharvaris has also filed an oral formulation of deucrictibant for on-demand treatment of HAE attacks with the U.S. FDA in June, with a decision expected by April 23, 2027. Analysts project peak sales for deucrictibant could reach $1 billion to $2 billion if both formulations are approved.
Rapid Read Rapid Read
Amprion Expands Parkinson's Disease Test to Europe Through Licensing Deal with MLM Medical Labs

Amprion Expands Parkinson's Disease Test to Europe Through Licensing Deal with MLM Medical Labs

Amprion, a diagnostics company based in San Diego, has announced a strategic licensing collaboration with MLM Medical Labs, a central and specialty laboratory group with operations in Germany, the U.S., and South Africa. This agreement will enable MLM Medical Labs to validate and run Amprion's proprietary seed amplification assay (SAA) methodology in-house at its German laboratory. The test, known as SAAmplify-αSYN, detects misfolded α-synuclein protein aggregates, which are indicative of conditions like Parkinson's disease, Lewy body dementia, and multiple system atrophy. This expansion aims to make the test accessible to biopharma sponsors conducting clinical trials across Europe, eliminating the need to ship samples across the Atlantic. The SAAmplify-αSYN test received Breakthrough Device Designation from the FDA in 2019 for aiding Parkinson's diagnosis and has been commercially available in the U.S. since 2021.
Trendline Trendline
RNAV8 Bio Collaborates with ARPA-H to Develop Programmable RNA Medicines

RNAV8 Bio Collaborates with ARPA-H to Develop Programmable RNA Medicines

RNAV8 Bio Collaborates with ARPA-H to Develop Programmable RNA Medicines
Trendline Trendline
Moderna and Merck Advance Personalized mRNA Cancer Vaccines, Focusing on Manufacturing Logistics and Cost

Moderna and Merck Advance Personalized mRNA Cancer Vaccines, Focusing on Manufacturing Logistics and Cost

Moderna and Merck Advance Personalized mRNA Cancer Vaccines, Focusing on Manufacturing Logistics and Cost
Rapid Read Rapid Read
Douglas Weber Leads Neurotechnology Research for Sensory and Motor Function Restoration

Douglas Weber Leads Neurotechnology Research for Sensory and Motor Function Restoration

Douglas Weber, a prominent researcher at Carnegie Mellon University, is leading efforts in neurotechnology to understand and restore sensory perception and motor control. His work integrates fundamental neuroscience with engineering to develop new technologies and therapies. Weber's research focuses on physiological mechanisms underlying sensory perception, feedback control of movement, and neuroplasticity in sensorimotor systems. He applies this knowledge to create solutions for individuals affected by stroke, spinal cord injury, or limb loss. Additionally, he is developing wearable devices aimed at enhancing sensory, motor, and cognitive functions in healthy individuals. Weber was a founding member of DARPA’s Biological Technologies Office, where he managed neurotechnology research programs supporting the White House BRAIN initiative launched by President Obama in 2013. His initiatives at DARPA included the HAPTIX, ElectRx, and TNT programs, which are developing implantable, injectable, and wearable neur...
Rapid Read Rapid Read
Merck and Moderna Announce Promising mRNA Cancer Vaccine Trial Results for Melanoma

Merck and Moderna Announce Promising mRNA Cancer Vaccine Trial Results for Melanoma

Pharmaceutical companies Merck and Moderna have announced hopeful human clinical trial results for individualized mRNA vaccines designed to protect against melanoma. This development marks a significant step in cancer treatment, utilizing the same messenger RNA (mRNA) technology that was foundational to the COVID-19 vaccines. The trials combined these personalized vaccines with an FDA-approved immunotherapy drug, leading to improved recurrence-free survival rates for patients. If approved by the FDA, this would be the first mRNA cancer treatment of its kind. Dr. Elias Sayour, a pediatric oncologist and professor at the University of Florida, highlighted the potential for this technology to create an entirely new class of personalized drugs capable of making previously incurable conditions curable. The process involves taking blood and cancer cell samples from a patient, sequencing their DNA and RNA to identify tumor mutations, and then creating a customized mRNA vaccine. This vaccine instructs the body's i...
Trendline Trendline
UCL Introduces Master's Program in Biotech and Pharmaceutical Management to Address Industry Demands

UCL Introduces Master's Program in Biotech and Pharmaceutical Management to Address Industry Demands

UCL Introduces Master's Program in Biotech and Pharmaceutical Management to Address Industry Demands
Rapid Read Rapid Read
BrainChild Bio Secures $116 Million Series A Funding to Advance Pediatric Brain Tumor CAR T-Cell Therapy

BrainChild Bio Secures $116 Million Series A Funding to Advance Pediatric Brain Tumor CAR T-Cell Therapy

BrainChild Bio, a biotechnology company, has successfully raised $116 million in Series A financing. This funding is primarily allocated to support the pivotal registrational trial for its lead candidate, BCB-276, an autologous chimeric antigen receptor (CAR) T-cell therapy. BCB-276 is designed to treat diffuse intrinsic pontine glioma (DIPG), a rare and aggressive pediatric brainstem tumor. The current standard of care for DIPG is radiation therapy, which offers limited options. The company has already dosed the first patient in its Phase II ILLUMINATE trial (NCT07680439), an open-label, single-arm study evaluating the efficacy and safety of BCB-276 in children and young adults with newly diagnosed DIPG following initial radiation therapy. The trial aims to accelerate the path to a future biologics license application (BLA) filing for BCB-276, which has received Fast Track designation from the FDA. The primary endpoint for the trial is overall survival, with secondary endpoints including safety, tolerabil...
Rapid Read Rapid Read
Heartburn Drug Vonoprazan Causes Fluorescent Yellow Urine in Patient, Highlighting Unusual Side Effect

Heartburn Drug Vonoprazan Causes Fluorescent Yellow Urine in Patient, Highlighting Unusual Side Effect

A 25-year-old woman participating in a Phase I clinical trial in Shanghai experienced a striking side effect: her urine turned a vivid fluorescent yellow, visible under ordinary room light. This phenomenon occurred after she ingested a 20-milligram tablet of vonoprazan fumarate, a stomach acid blocker sold in the United States as Voquezna. The fluorescent urine appeared after the first dose, disappeared when the drug cleared her system, and reappeared upon subsequent dosing. Despite the dramatic visual change, the woman reported feeling fine, and her laboratory results remained normal throughout the trial. This case, documented by Lei Sheng and Xuening Li of the Department of Clinical Pharmacology at Zhongshan Hospital, Fudan University, is significant because fluorescent urine is typically associated with serious medical conditions like ethylene glycol poisoning or porphyria, which usually require ultraviolet light for detection. The authors noted that the visibility of the fluorescence in ambient light i...
Rapid Read Rapid Read
AI-Generated Drug Candidate Rentosertib Shows Potential for Anti-Aging and Lung Disease Treatment

AI-Generated Drug Candidate Rentosertib Shows Potential for Anti-Aging and Lung Disease Treatment

An AI-generated drug candidate, rentosertib, developed by Insilico Medicine, has demonstrated potential in slowing aging and treating a chronic lung disease. The drug's molecular structure was created with the assistance of artificial intelligence. Clinical trial results, published in Nature Biotechnology, indicate that rentosertib successfully reduced biological markers associated with aging. While these findings are promising, the drug is still several years away from potential regulatory approval. It is important to note that the anti-aging effects of rentosertib have not yet been tested in healthy patients, with current research focusing on its impact on biological markers rather than direct anti-aging outcomes in a broader population. The development highlights the growing role of AI in drug discovery and its potential to accelerate the identification and creation of novel therapeutic compounds for complex conditions.
Trendline Trendline
BioNTech Shares Decline Following BMO Capital Downgrade Amidst Reduced COVID Vaccine Demand and Clinical Trial Termination

BioNTech Shares Decline Following BMO Capital Downgrade Amidst Reduced COVID Vaccine Demand and Clinical Trial Termination

BioNTech Shares Decline Following BMO Capital Downgrade Amidst Reduced COVID Vaccine Demand and Clinical Trial Termination
Trendline Trendline
Global Microbiome Therapeutics Market Projected to Reach $4.6 Billion by 2035 Amidst Clinical and Regulatory Advancements

Global Microbiome Therapeutics Market Projected to Reach $4.6 Billion by 2035 Amidst Clinical and Regulatory Advancements

Global Microbiome Therapeutics Market Projected to Reach $4.6 Billion by 2035 Amidst Clinical and Regulatory Advancements